(Q34455226)

2 August 2017

1 reference

title

VHL, the story of a tumour suppressor gene (English)

1 reference

2 August 2017

3

Eamonn R Maher

1 reference

2 August 2017

Lucy Gossage

1

1 reference

2 August 2017

Tim Eisen

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

2 August 2017

published in

Nature Reviews Cancer

1 reference

2 August 2017

volume

15

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

55-64

1 reference

Über eine sehr seltene Erkrankung der Netzhaut

2 August 2017

cites work

1 reference

ZUR FRAGE DER ANGIOMATOSIS RETINae UND IHRER HIRNKOMPLIKATIONEN

21 January 2018

1 reference

von Hippel-Lindau disease: a clinical and scientific review

21 January 2018

1 reference

LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED.

21 January 2018

1 reference

Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus

21 January 2018

1 reference

Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus

21 January 2018

1 reference

Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype

21 January 2018

1 reference

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

21 January 2018

1 reference

Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma

21 January 2018

1 reference

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

Tumour suppression by the human von Hippel-Lindau gene product

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal

21 January 2018

1 reference

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity

21 January 2018

1 reference

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation

21 January 2018

1 reference

A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

21 January 2018

1 reference

Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein

21 January 2018

1 reference

Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C

21 January 2018

1 reference

Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function

21 January 2018

1 reference

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

21 January 2018

1 reference

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase

21 January 2018

1 reference

The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins

21 January 2018

1 reference

Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products

21 January 2018

1 reference

Integrated molecular analysis of clear-cell renal cell carcinoma

21 January 2018

1 reference

Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

21 January 2018

1 reference

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

21 January 2018

1 reference

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL

21 January 2018

1 reference

Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling

21 January 2018

1 reference

A conserved family of prolyl-4-hydroxylases that modify HIF

21 January 2018

1 reference

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

21 January 2018

1 reference

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

21 January 2018

1 reference

HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation

21 January 2018

1 reference

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

21 January 2018

1 reference

Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis

21 January 2018

1 reference

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

21 January 2018

1 reference

Oxygen sensing, homeostasis, and disease

21 January 2018

1 reference

Emerging roles of microRNAs in the molecular responses to hypoxia

21 January 2018

1 reference

The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.

21 January 2018

1 reference

Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha

21 January 2018

1 reference

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

21 January 2018

1 reference

Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.

21 January 2018

1 reference

von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination

21 January 2018

1 reference

Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation

21 January 2018

1 reference

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

21 January 2018

1 reference

Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway

21 January 2018

1 reference

Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo

21 January 2018

1 reference

Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo

21 January 2018

1 reference

Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice

21 January 2018

1 reference

Hypoxia-inducible factor 2 regulates hepatic lipid metabolism

21 January 2018

1 reference

Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice

21 January 2018

1 reference

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

21 January 2018

1 reference

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

21 January 2018

1 reference

Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene

21 January 2018

1 reference

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis

21 January 2018

1 reference

Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.

21 January 2018

1 reference

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

21 January 2018

1 reference

Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans

21 January 2018

1 reference

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

21 January 2018

1 reference

Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.

21 January 2018

1 reference

Software and database for the analysis of mutations in the VHL gene

21 January 2018

1 reference

Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients

21 January 2018

1 reference

Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location.

21 January 2018

1 reference

Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients

21 January 2018

1 reference

Genotype-phenotype correlations in von Hippel-Lindau disease.

21 January 2018

1 reference

Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.

21 January 2018

1 reference

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

21 January 2018

1 reference

Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma

21 January 2018

1 reference

An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects

21 January 2018

1 reference

Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

21 January 2018

1 reference

Mutations in the VHL gene in sporadic apparently congenital polycythemia

21 January 2018

1 reference

Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.

21 January 2018

1 reference

The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W).

21 January 2018

1 reference

Genetic basis of congenital erythrocytosis: mutation update and online databases

21 January 2018

1 reference

Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia

21 January 2018

1 reference

Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

21 January 2018

1 reference

The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.

21 January 2018

1 reference

Acute postnatal ablation of Hif-2alpha results in anemia

21 January 2018

1 reference

HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner

21 January 2018

1 reference

Mutation and cancer: statistical study of retinoblastoma

21 January 2018

1 reference

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

21 January 2018

1 reference

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

Alterations in VHL as potential biomarkers in renal-cell carcinoma

21 January 2018

1 reference

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

21 January 2018

1 reference

BAP1 loss defines a new class of renal cell carcinoma

21 January 2018

1 reference

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

21 January 2018

1 reference

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.

21 January 2018

1 reference

Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma

21 January 2018

1 reference

VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations

21 January 2018

1 reference

Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system

21 January 2018

1 reference

Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas

21 January 2018

1 reference

Germ-line mutations in nonsyndromic pheochromocytoma

21 January 2018

1 reference

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

21 January 2018

1 reference

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

21 January 2018

1 reference

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

21 January 2018

1 reference

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

21 January 2018

1 reference

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

21 January 2018

1 reference

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron

21 January 2018

1 reference

Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor

21 January 2018

1 reference

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis

21 January 2018

1 reference

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma

21 January 2018

1 reference

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

21 January 2018

1 reference

Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.

21 January 2018

1 reference

Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency

21 January 2018

1 reference

Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.

21 January 2018

1 reference

Molecular genetics of clear-cell renal cell carcinoma

21 January 2018

1 reference

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma

21 January 2018

1 reference

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

Treatment selection in metastatic renal cell carcinoma: expert consensus

21 January 2018

1 reference

Allosteric inhibition of hypoxia inducible factor-2 with small molecules

21 January 2018

1 reference

Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor

21 January 2018

1 reference

Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface

21 January 2018

1 reference

Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site.

21 January 2018

1 reference

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

21 January 2018

1 reference

Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing

21 January 2018

1 reference

A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.

21 January 2018

1 reference

Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression.

21 January 2018

1 reference

Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression

21 January 2018

1 reference

Molecular pathways in renal cell carcinoma--rationale for targeted treatment

21 January 2018

1 reference

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy

21 January 2018

1 reference

Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.

21 January 2018

1 reference

Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.

21 January 2018

1 reference

Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis

21 January 2018

1 reference

Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

21 January 2018

1 reference

Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor

21 January 2018

1 reference

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

21 January 2018

1 reference

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

21 January 2018

1 reference

Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor.

21 January 2018

1 reference

VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail

21 January 2018

1 reference

Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin

21 January 2018

1 reference

Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase

21 January 2018

1 reference

Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma

21 January 2018

1 reference

pVHL function is essential for endothelial extracellular matrix deposition.

21 January 2018

1 reference

Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix

21 January 2018

1 reference

pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development

21 January 2018

1 reference

Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation

21 January 2018

1 reference

Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

21 January 2018

1 reference

Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.

21 January 2018

1 reference

VHL loss causes spindle misorientation and chromosome instability.

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth

21 January 2018

1 reference

Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

Primary cilium formation requires von hippel-lindau gene function in renal-derived cells

21 January 2018

1 reference

The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance.

21 January 2018

1 reference

Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability

21 January 2018

1 reference

Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics

21 January 2018

1 reference

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells

21 January 2018

1 reference

Binding of natively unfolded HIF-1alpha ODD domain to p53

21 January 2018

1 reference

HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase

21 January 2018

1 reference

VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.

21 January 2018

1 reference

NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas

21 January 2018

1 reference

p53 stabilization and transactivation by a von Hippel-Lindau protein

21 January 2018

1 reference

The positive regulation of p53 by the tumor suppressor VHL.

21 January 2018

1 reference

pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2

21 January 2018

1 reference

Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer

21 January 2018

1 reference

VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400.

21 January 2018

1 reference

Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress

21 January 2018

1 reference

von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.

21 January 2018

1 reference

Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells

21 January 2018

1 reference

An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity

21 January 2018

1 reference

Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.

21 January 2018

1 reference

Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes

21 January 2018

1 reference

Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma

21 January 2018

1 reference

Specific genetic change in tumors associated with von Hippel-Lindau disease

21 January 2018

1 reference

Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours

31 March 2020

1 reference

Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma

31 March 2020

1 reference

Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition

31 March 2020

1 reference

Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.

31 March 2020

1 reference

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

31 March 2020

1 reference

Genotype-phenotype correlations in VHL exon deletions

31 March 2020

1 reference

Von hippel-lindau disease and erythrocytosis

31 March 2020

1 reference

Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system

31 March 2020

1 reference

Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development

31 March 2020

1 reference

Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways

31 March 2020

1 reference

Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2

31 March 2020

1 reference

Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation

31 March 2020

1 reference

Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma

31 March 2020

1 reference

von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter

31 March 2020

1 reference

[Results of mutation analyses of von Hippel-Lindau disease gene in Japanese patients: comparison with results in United States and United Kingdom]

31 March 2020

1 reference

12 December 2020

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

1 reference

12 December 2020

Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).

1 reference

12 December 2020

von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis

1 reference

12 December 2020

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis

1 reference

12 December 2020

VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.

1 reference

12 December 2020

Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions

1 reference

12 December 2020

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality

1 reference

12 December 2020

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

1 reference

12 December 2020

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

1 reference

12 December 2020

The Catalogue of Somatic Mutations in Cancer (COSMIC)

1 reference

12 December 2020

The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway

1 reference

12 December 2020

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

1 reference

12 December 2020

Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas

1 reference

12 December 2020

Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function

1 reference

12 December 2020

Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations

1 reference

12 December 2020

Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways

1 reference

12 December 2020

Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor

1 reference

12 December 2020

Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia

1 reference

12 December 2020

Genetic analysis of von Hippel-Lindau disease.

1 reference

12 December 2020

Von Hippel-Lindau disease in a Newfoundland kindred

1 reference

12 December 2020

Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits

1 reference

12 December 2020

A rationally designed small molecule that inhibits the HIF-1alpha-ARNT heterodimer from binding to DNA in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3844

1 reference

Dimensions Publication ID

2 August 2017

1009041579

0 references

1 reference